Ipratropiumbromid+fenoterolhydrobromid Farmak

Ipratropium bromide / Fenoterol hydrobromide, the active ingredient in Ipratropiumbromid+fenoterolhydrobromid Farmak, is an anticholinergic bronchodilator and short‑acting β2‑agonist presented as an inhalation solution for inhalation use. It provides bronchodilation for patients with asthma and chronic obstructive pulmonary disease.

GNH USA supplies Ipratropiumbromid+fenoterolhydrobromid Farmak as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium bromide / Fenoterol hydrobromide acts on the airway smooth muscle to improve airflow in obstructive lung diseases. - Asthma: improves airway opening and reduces wheezing, shortness of breath and rescue medication use. - Chronic obstructive pulmonary disease (COPD): enhances airflow, decreases dyspnea and helps prevent exacerbations. - Acute bronchospasm: provides rapid bronchodilation for relief of sudden airway constriction.

The following adverse reactions have been reported with the combined inhalation solution.

Common Side Effects: - Dry mouth: reduced salivary secretion. - Cough or throat irritation: local irritation from the aerosol. - Headache: mild to moderate intensity. - Tremor: fine muscle tremor, often transient. - Palpitations: awareness of heartbeat. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Paradoxical bronchospasm: worsening airway constriction after inhalation. - Angioedema: swelling of face, lips or tongue. - Severe tachyarrhythmia: rapid heart rhythm requiring medical attention. - Anaphylactic reaction: systemic allergic response with hypotension and airway compromise.

Before prescribing the inhalation solution, clinicians should consider the following safety measures. - Assess renal function: adjust therapy in severe impairment. - Monitor heart rate: watch for tachycardia or arrhythmias. - Avoid use in patients with known hypersensitivity to either component. - Use with caution in cardiovascular disease: may increase heart workload. - Pregnancy and lactation: consult a physician as safety data are limited. - Store at room temperature: keep in original container, protect from moisture and light.

Potential drug interactions should be reviewed prior to initiating therapy.

Major Interactions (Avoid): - Beta‑blockers: may blunt bronchodilator effect. - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis with fenoterol. - Concurrent anticholinergics: may increase anticholinergic side effects.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypokalemia. - Theophylline: increased risk of tachyarrhythmia. - Systemic corticosteroids: may enhance systemic adrenergic effects.